Compared with individuals in the metformin and second- or third-line glucose-lowering medications groups, major CVEs were significantly lower in individuals with NAFLD and type 2 diabetes who received GLP-1RAs but not different from those who received SGLT2 inhibitors
Impact Of Supply Stabilization As supply conditions improve throughout 2026: Shortage-based compounding justifications may narrow Regulatory flexibility may decrease Product-specific scrutiny may increase Enforcement activities may expand Organizations relying on shortage-related exemptions should continuously monitor current FDA shortage determinations
For those with type 2 diabetes, this often means trying metformin first before advancing to a GLP-1
Weight Loss Efficacy Current data suggests the injectable form may produce slightly more weight loss for some patients
By focusing on dietary modifications, intermittent fasting, and specific medications like LDN and GLP-1 agonists, individuals can take pro active steps to reduce inflammation and improve their overall health
Acta Odontol Scand 69(5):263268
